Last reviewed · How we verify
Chronic kidney disease at increased risk of cardiovascular disease
Approved treatments
- Inpefa · Lexicon Pharms Inc
Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic kidney disease at increased risk of cardiovascular disease patent landscape — cliff calendar, originator estates, attackable patents
- Chronic kidney disease at increased risk of cardiovascular disease treatment landscape brief
- Chronic kidney disease at increased risk of cardiovascular disease treatment updates RSS
Frequently asked questions about Chronic kidney disease at increased risk of cardiovascular disease
What drugs treat Chronic kidney disease at increased risk of cardiovascular disease?
Tracked treatments include Inpefa.
What is the treatment for Chronic kidney disease at increased risk of cardiovascular disease?
Standard treatment for Chronic kidney disease at increased risk of cardiovascular disease includes Inpefa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic kidney disease at increased risk of cardiovascular disease patent cliff · Chronic kidney disease at increased risk of cardiovascular disease CI report
- Treatment: Inpefa · Lexicon Pharms Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing